how to define & measure clinical endpoints to optimize your oncology drug dosing
Published 1 year ago • 1.1K plays • Length 55:19Download video MP4
Download video MP3
Similar videos
-
42:27
what you should know about fda project optimus for your oncology drug approval
-
45:33
using model-based meta-analysis to improve decision-making in drug development
-
31:44
echalk talk: how oncology drug developers can prepare for fda’s project optimus
-
39:27
the physiological basis of comparative pharmacokinetics
-
57:36
project optimus & pediatric drug development
-
45:59
measurements for ctdi calculation
-
7:42
grammetry: day-of-surgery record capture using the combiguide
-
11:15
chorioallantoic membrane (cam) assay: tools and techniques | jptv
-
22:18
seeking answers: ocular melanoma making strides
-
59:00
what is fda project optimus and how will it impact oncology drug development?
-
54:26
what oncology drug developers should expect from the fda’s project optimus
-
33:21
using model based meta analysis to inform drug development for auto immune diseases
-
28:02
29 schilsky - optimizing safety data collection in cancer clinical trials
-
39:10
the changing nature of phase i trials
-
1:00:21
optimize drug development with public data and predictive models – model-based meta-analysis (mbma)
-
43:04
how model-based approaches can improve precision dosing in clinical care
-
8:32
dose optimization for improved outcomes in refractory mcrc
-
1:05:56
leveraging modeling and simulation for neonatal and infant drug development
-
5:57
panel 2 — incorporating patient reported outcomes to inform dose selection and optimization
-
59:36
accelerating early stage develpment with simulation and biomarkers
-
1:00:17
webinar: clinical endpoints and treatment effect in immuno oncology